Group 1 - The company, Weigao Group, has signed a non-binding letter of intent to acquire 100% of Weigao Puri's shares through Weigao Blood Purification, which will issue consideration shares to Weigao Puri's shareholders [1] - Weigao Blood Purification is primarily engaged in the research, production, and sales of blood purification medical products, including hemodialyzers and peritoneal dialysis solutions [1] - Weigao Puri focuses on the development and production of pre-filled drug delivery systems and automatic safety drug delivery systems, providing comprehensive drug delivery solutions for global biopharmaceutical companies [1] Group 2 - The board believes that if the potential transaction is completed, there will be synergies between Weigao Puri and Weigao Blood Purification, further expanding the overall business landscape of the group [2]

Core Points - Weigao Blood Purification (603014.SH) is planning to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. through a share issuance, which will make Weigao Purui a wholly-owned subsidiary of the company [1] - The transaction is expected to constitute a major asset restructuring and related party transaction, but will not lead to a change in the actual controller of the company and does not constitute a restructuring listing [1] - The company has signed a Cooperation Intent Agreement with the transaction parties, outlining the preliminary intentions for the acquisition [1] Summary by Sections - **Transaction Details** - The acquisition is still in the planning stage, and the parties have not yet signed a formal transaction agreement [2] - The specific transaction plan is under negotiation and remains uncertain [2] - **Regulatory Approval** - The transaction requires approval from the company's board of directors, shareholders, and relevant regulatory authorities before it can be officially implemented [2] - There is uncertainty regarding whether the necessary approvals will be obtained and the timeline for such approvals [2] - **Stock Suspension** - To protect investor interests and ensure fair information disclosure, the company has applied for a trading suspension starting from October 20, 2025, for a period not exceeding 10 trading days [1]

Core Viewpoint - Weigao Group has signed a non-binding letter of intent for a potential acquisition of 100% equity in Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd by Weigao Blood Purification Products Co., Ltd, indicating strategic expansion in the pharmaceutical packaging sector [1][2] Group 1: Company Overview - Weigao Blood Purification Products Co., Ltd is primarily engaged in the research, production, and sales of medical products for blood purification, including hemodialyzers, blood dialysis tubing, dialysis machines, and peritoneal dialysis solutions [1] - As of the announcement date, Weigao Blood Purification is controlled by Weigao Group, which holds a 23.53% direct stake in the company [1] Group 2: Weigao Purui Overview - Weigao Purui focuses on the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems, aiming to provide comprehensive drug delivery solutions for global biopharmaceutical companies [2] - Weigao Purui is a non-wholly owned subsidiary of the company, with ownership stakes of 94.0706% by the company, 4.0215% by Weihai Shengxi, and 1.9078% by Weihai Ruiming [2]

Group 1 - Weigao Group has signed a non-binding letter of intent for a potential acquisition of 100% equity in Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd by Weigao Blood Purification [1] - The potential transaction involves issuing consideration shares to Weigao Purui shareholders, which include Weigao Group and its affiliates [1] - Weigao Blood Purification is primarily engaged in the research, production, and sales of medical products for blood purification, including hemodialysis devices and peritoneal dialysis solutions [1] Group 2 - Weigao Purui focuses on the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems, providing comprehensive drug delivery solutions for global biopharmaceutical companies [2] - As of the announcement date, Weigao Purui is a non-wholly owned subsidiary of the company, with ownership stakes of 94.0706%, 4.0215%, and 1.9078% held by the company, Weihai Shengxi, and Weihai Ruiming, respectively [2]

山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 威高普瑞聚焦預灌封給藥系統及自動安全給藥系統等醫藥包材的研發、生產 與銷售，致力於為全球生物製藥企業提供一站式藥品遞送整體解決方案。截 至本公告日期，威高普瑞為本公司的非全資附屬公司，由本公司、威海盛熙和 威海瑞明分別持有94.0706%、4.0215%及1.9078%的股權。 董事會認為，潛在交易若可完成，威高普瑞與威高血淨在業務上將產生協同 效應，本集團整體業務版圖將進一步擴大。 上市規則涵義 自願公告 本公告乃由山東威高集團醫用高分子製品股份有限公司（「本公司」，連同其附 屬公司合稱「本集團」）自願刊發。 潛在交易 本公司董事會（「董事會」）謹此宣佈，於2025年10月17日（ ...

威高血净公告，公司正在筹划以发行股份的方式购买山东威高普瑞医药包装有限公司100%股权。本次 交易完成后，威高普瑞将成为公司的全资子公司。本次交易预计构成重大资产重组，构成关联交易，但 不会导致公司实际控制人的变更。目前，交易尚处于筹划阶段，存在不确定性。公司股票自2025年10月 20日起停牌，预计停牌时间不超过10个交易日。 ...

（记者 胡玲） 每经AI快讯，威高血净10月17日晚间发布公告称，因公司筹划发行股份购买资产暨关联交易事项山东 威高血液净化制品股份有限公司正在筹划以发行股份的方式购买山东威高普瑞医药包装有限公司100% 股权。本次交易完成后，威高普瑞将成为公司的全资子公司。经初步测算，本次交易预计构成重大资产 重组，构成关联交易。本次交易不会导致公司实际控制人的变更，不构成重组上市。为了维护投资者利 益，保证公平信息披露，避免对公司股价造成重大影响，经公司申请，公司股票自2025年10月20日（星 期一）开市起停牌，预计停牌时间不超过10个交易日。 每经头条（nbdtoutiao）——"我还在！"林园硬气回应牛市亏钱，"接下来，我还会在！"坚持白酒是"快 乐需求"，科技股买了"愁得睡不着" ...

证券代码：603014 证券简称：威高血净 公告编号：2025-033 山东威高血液净化制品股份有限公司 关于筹划发行股份购买资产 暨关联交易事项的停牌公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 证券代码 | 证券简称 | 停复牌类型 | | 停牌起始日 | 停牌期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603014 | 威高血净 | A 股 | 停牌 | 2025/10/20 | | | | | 公司名称 | 山东威高集团医用高分子制品股份有限公司 | | --- | --- | | 企业类型 | 股份有限公司（台港澳与境内合资、上市） | | 注册地址 | 山东省威海火炬高技术产业开发区威高路 号 1 | | 法定代表人 | 龙经 | | 注册资本 | 万元 45,706.32324 | | 统一社会信用代码 | 91370000726685299F | | 成立时间 | 2000 年 12 月 ...

威高血净公告，公司正在筹划以发行股份的方式购买山东威高普瑞医药包装有限公司100%股权。本次 交易预计构成重大资产重组，构成关联交易，但不会导致公司实际控制人的变更。目前，交易尚处于筹 划阶段，存在不确定性。公司股票自2025年10月20日起停牌，预计停牌时间不超过10个交易日。 ...

（编辑 楚丽君） 证券日报网讯 10月16日晚间，威高血净发布公告称，2025年半年度利润分配方案为A股每股现金红利 0.15756元（含税），股权登记日为2025年10月23日，除权（息）日及现金红利发放日均为2025年10月 24日。 ...